vs
ANI PHARMACEUTICALS INC（ANIP）とTecnoglass Inc.（TGLS）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $245.3M、Tecnoglass Inc.の約1.0倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 10.6%、差は0.5%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 2.4%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $11.4M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 12.8%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
テクノグラス社は高性能建築用ガラス、アルミ製の窓やドア、関連建築部品を製造するリーディング企業で、主に北米及びラテンアメリカの住宅・商業建築分野向けに、新築・改修プロジェクト用のカスタマイズされた省エネルギーソリューションを提供している。
ANIP vs TGLS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $245.3M |
| 純利益 | $27.5M | $26.1M |
| 粗利率 | — | 40.0% |
| 営業利益率 | 14.1% | 18.3% |
| 純利益率 | 11.1% | 10.6% |
| 売上前年比 | 29.6% | 2.4% |
| 純利益前年比 | 367.5% | -44.5% |
| EPS（希薄化後） | $1.14 | $0.57 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $245.3M | ||
| Q3 25 | $227.8M | $260.5M | ||
| Q2 25 | $211.4M | $255.5M | ||
| Q1 25 | $197.1M | $222.3M | ||
| Q4 24 | $190.6M | $239.6M | ||
| Q3 24 | $148.3M | $238.3M | ||
| Q2 24 | $138.0M | $219.7M | ||
| Q1 24 | $137.4M | $192.6M |
| Q4 25 | $27.5M | $26.1M | ||
| Q3 25 | $26.6M | $47.2M | ||
| Q2 25 | $8.5M | $44.1M | ||
| Q1 25 | $15.7M | $42.2M | ||
| Q4 24 | $-10.3M | $47.0M | ||
| Q3 24 | $-24.2M | $49.5M | ||
| Q2 24 | $-2.3M | $35.0M | ||
| Q1 24 | $18.2M | $29.7M |
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | 43.9% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 40.8% | ||
| Q1 24 | — | 38.8% |
| Q4 25 | 14.1% | 18.3% | ||
| Q3 25 | 15.9% | 25.1% | ||
| Q2 25 | 6.6% | 24.0% | ||
| Q1 25 | 13.3% | 26.7% | ||
| Q4 24 | -2.3% | 28.0% | ||
| Q3 24 | -13.8% | 28.4% | ||
| Q2 24 | 3.7% | 23.3% | ||
| Q1 24 | 14.8% | 21.3% |
| Q4 25 | 11.1% | 10.6% | ||
| Q3 25 | 11.7% | 18.1% | ||
| Q2 25 | 4.0% | 17.3% | ||
| Q1 25 | 8.0% | 19.0% | ||
| Q4 24 | -5.4% | 19.6% | ||
| Q3 24 | -16.3% | 20.8% | ||
| Q2 24 | -1.7% | 15.9% | ||
| Q1 24 | 13.2% | 15.4% |
| Q4 25 | $1.14 | $0.57 | ||
| Q3 25 | $1.13 | $1.01 | ||
| Q2 25 | $0.36 | $0.94 | ||
| Q1 25 | $0.69 | $0.90 | ||
| Q4 24 | $-0.45 | $1.00 | ||
| Q3 24 | $-1.27 | $1.05 | ||
| Q2 24 | $-0.14 | $0.75 | ||
| Q1 24 | $0.82 | $0.63 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $104.1M |
| 総負債低いほど良い | — | $174.4M |
| 株主資本純資産 | $540.7M | $713.1M |
| 総資産 | $1.4B | $1.3B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.24× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $104.1M | ||
| Q3 25 | $262.6M | $127.1M | ||
| Q2 25 | $217.8M | $140.9M | ||
| Q1 25 | $149.8M | $160.2M | ||
| Q4 24 | $144.9M | $137.5M | ||
| Q3 24 | $145.0M | $124.8M | ||
| Q2 24 | $240.1M | $129.5M | ||
| Q1 24 | $228.6M | $138.8M |
| Q4 25 | — | $174.4M | ||
| Q3 25 | — | $114.7M | ||
| Q2 25 | — | $110.6M | ||
| Q1 25 | — | $110.6M | ||
| Q4 24 | — | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M | ||
| Q1 24 | — | $160.9M |
| Q4 25 | $540.7M | $713.1M | ||
| Q3 25 | $505.8M | $764.0M | ||
| Q2 25 | $436.8M | $736.0M | ||
| Q1 25 | $418.6M | $685.1M | ||
| Q4 24 | $403.7M | $631.2M | ||
| Q3 24 | $405.9M | $613.3M | ||
| Q2 24 | $455.8M | $574.8M | ||
| Q1 24 | $452.0M | $573.6M |
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.0B | ||
| Q3 24 | $1.3B | $996.3M | ||
| Q2 24 | $920.8M | $942.5M | ||
| Q1 24 | $914.5M | $981.6M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× | ||
| Q1 24 | — | 0.28× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $31.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $11.4M |
| FCFマージンFCF / 売上 | 11.8% | 4.7% |
| 設備投資強度設備投資 / 売上 | 0.5% | 8.0% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 1.19× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $34.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $31.0M | ||
| Q3 25 | $44.1M | $40.0M | ||
| Q2 25 | $75.8M | $17.9M | ||
| Q1 25 | $35.0M | $46.9M | ||
| Q4 24 | $15.9M | $61.1M | ||
| Q3 24 | $12.5M | $41.5M | ||
| Q2 24 | $17.4M | $34.5M | ||
| Q1 24 | $18.3M | $33.4M |
| Q4 25 | $29.1M | $11.4M | ||
| Q3 25 | $38.0M | $21.2M | ||
| Q2 25 | $71.8M | $-14.7M | ||
| Q1 25 | $32.5M | $16.5M | ||
| Q4 24 | $13.5M | $35.4M | ||
| Q3 24 | $7.7M | $17.8M | ||
| Q2 24 | $13.0M | $14.2M | ||
| Q1 24 | $13.7M | $23.6M |
| Q4 25 | 11.8% | 4.7% | ||
| Q3 25 | 16.7% | 8.2% | ||
| Q2 25 | 34.0% | -5.7% | ||
| Q1 25 | 16.5% | 7.4% | ||
| Q4 24 | 7.1% | 14.8% | ||
| Q3 24 | 5.2% | 7.5% | ||
| Q2 24 | 9.4% | 6.5% | ||
| Q1 24 | 10.0% | 12.2% |
| Q4 25 | 0.5% | 8.0% | ||
| Q3 25 | 2.7% | 7.2% | ||
| Q2 25 | 1.9% | 12.7% | ||
| Q1 25 | 1.3% | 13.7% | ||
| Q4 24 | 1.3% | 10.7% | ||
| Q3 24 | 3.2% | 9.9% | ||
| Q2 24 | 3.2% | 9.2% | ||
| Q1 24 | 3.3% | 5.1% |
| Q4 25 | 1.10× | 1.19× | ||
| Q3 25 | 1.66× | 0.85× | ||
| Q2 25 | 8.87× | 0.41× | ||
| Q1 25 | 2.23× | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | 1.00× | 1.13× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
